Akari Therapeutics Plc Sponsored ADR Forecast, price target & analysts
$0.49
1.46%
today
Nasdaq,
Nov 20, 06:49 pm CET
Akari Therapeutics Plc Sponsored ADR Target price 2025 - Analyst rating & recommendation
Powered by
Akari Therapeutics Plc Sponsored ADR Classifications & Recommendation:
Buy
89%
Hold
11%
Akari Therapeutics Plc Sponsored ADR Price Target
| Target Price | $5.10 |
| Price | $0.50 |
| Potential |
922.66%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Akari Therapeutics Plc Sponsored ADR 2026 .
The average Akari Therapeutics Plc Sponsored ADR target price is $5.10.
This is
922.66%
register free of charge
$7.35
1,373.83%
register free of charge
$1.62
224.04%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Akari Therapeutics Plc Sponsored ADR to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Akari Therapeutics Plc Sponsored ADR stock has an average upside potential 2026 of
922.66%
register free of charge
|
Current Akari Therapeutics Plc Sponsored ADR Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 09 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Jul 18 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 09 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Jul 18 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
